Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration on for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5% in 15 g and 30 g tubes, a generic version of reference listed drug ZOVIRAX (acyclovir) Ointment 5%. For more updates, please feel free to email us info@solaris-pharma.com
top of page
Search
Recent Posts
See AllSolaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its...
bottom of page
Comentarios